|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARIH2 |
Gene summary for ARIH2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARIH2 | Gene ID | 10425 |
| Gene name | ariadne RBR E3 ubiquitin protein ligase 2 | |
| Gene Alias | ARI2 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | O95376 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10425 | ARIH2 | LZE4T | Human | Esophagus | ESCC | 7.82e-15 | 3.24e-01 | 0.0811 |
| 10425 | ARIH2 | LZE7T | Human | Esophagus | ESCC | 1.93e-08 | 5.29e-01 | 0.0667 |
| 10425 | ARIH2 | LZE8T | Human | Esophagus | ESCC | 1.52e-08 | 1.74e-01 | 0.067 |
| 10425 | ARIH2 | LZE22D1 | Human | Esophagus | HGIN | 1.47e-04 | 1.09e-01 | 0.0595 |
| 10425 | ARIH2 | LZE22T | Human | Esophagus | ESCC | 1.28e-02 | 3.55e-01 | 0.068 |
| 10425 | ARIH2 | LZE24D1 | Human | Esophagus | HGIN | 2.00e-02 | 4.02e-01 | 0.054 |
| 10425 | ARIH2 | LZE24T | Human | Esophagus | ESCC | 1.01e-23 | 5.73e-01 | 0.0596 |
| 10425 | ARIH2 | LZE6T | Human | Esophagus | ESCC | 9.15e-04 | 1.71e-01 | 0.0845 |
| 10425 | ARIH2 | P1T-E | Human | Esophagus | ESCC | 3.36e-09 | 3.12e-01 | 0.0875 |
| 10425 | ARIH2 | P2T-E | Human | Esophagus | ESCC | 1.01e-18 | 3.87e-01 | 0.1177 |
| 10425 | ARIH2 | P4T-E | Human | Esophagus | ESCC | 2.40e-26 | 7.56e-01 | 0.1323 |
| 10425 | ARIH2 | P5T-E | Human | Esophagus | ESCC | 2.60e-06 | 2.07e-01 | 0.1327 |
| 10425 | ARIH2 | P8T-E | Human | Esophagus | ESCC | 4.80e-21 | 3.28e-01 | 0.0889 |
| 10425 | ARIH2 | P9T-E | Human | Esophagus | ESCC | 1.25e-12 | 3.49e-01 | 0.1131 |
| 10425 | ARIH2 | P10T-E | Human | Esophagus | ESCC | 4.40e-20 | 4.28e-01 | 0.116 |
| 10425 | ARIH2 | P11T-E | Human | Esophagus | ESCC | 3.80e-16 | 5.33e-01 | 0.1426 |
| 10425 | ARIH2 | P12T-E | Human | Esophagus | ESCC | 4.17e-26 | 6.51e-01 | 0.1122 |
| 10425 | ARIH2 | P15T-E | Human | Esophagus | ESCC | 1.34e-21 | 4.95e-01 | 0.1149 |
| 10425 | ARIH2 | P16T-E | Human | Esophagus | ESCC | 2.75e-20 | 4.95e-01 | 0.1153 |
| 10425 | ARIH2 | P17T-E | Human | Esophagus | ESCC | 2.02e-04 | 2.60e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00104987 | Liver | NAFLD | proteasomal protein catabolic process | 101/1882 | 490/18723 | 1.35e-12 | 6.09e-10 | 101 |
| GO:00421767 | Liver | NAFLD | regulation of protein catabolic process | 83/1882 | 391/18723 | 2.94e-11 | 1.01e-08 | 83 |
| GO:19030507 | Liver | NAFLD | regulation of proteolysis involved in cellular protein catabolic process | 53/1882 | 221/18723 | 1.32e-09 | 2.34e-07 | 53 |
| GO:20000587 | Liver | NAFLD | regulation of ubiquitin-dependent protein catabolic process | 43/1882 | 164/18723 | 2.66e-09 | 4.20e-07 | 43 |
| GO:19033627 | Liver | NAFLD | regulation of cellular protein catabolic process | 56/1882 | 255/18723 | 1.38e-08 | 1.71e-06 | 56 |
| GO:00002095 | Liver | NAFLD | protein polyubiquitination | 51/1882 | 236/18723 | 1.04e-07 | 8.10e-06 | 51 |
| GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
| GO:00457327 | Liver | NAFLD | positive regulation of protein catabolic process | 48/1882 | 231/18723 | 8.22e-07 | 4.45e-05 | 48 |
| GO:00611367 | Liver | NAFLD | regulation of proteasomal protein catabolic process | 40/1882 | 187/18723 | 3.12e-06 | 1.26e-04 | 40 |
| GO:00458627 | Liver | NAFLD | positive regulation of proteolysis | 65/1882 | 372/18723 | 6.58e-06 | 2.29e-04 | 65 |
| GO:00324347 | Liver | NAFLD | regulation of proteasomal ubiquitin-dependent protein catabolic process | 31/1882 | 134/18723 | 7.40e-06 | 2.55e-04 | 31 |
| GO:00512227 | Liver | NAFLD | positive regulation of protein transport | 55/1882 | 303/18723 | 1.07e-05 | 3.35e-04 | 55 |
| GO:00709364 | Liver | NAFLD | protein K48-linked ubiquitination | 19/1882 | 65/18723 | 1.33e-05 | 3.97e-04 | 19 |
| GO:00485884 | Liver | NAFLD | developmental cell growth | 45/1882 | 234/18723 | 1.50e-05 | 4.38e-04 | 45 |
| GO:19049517 | Liver | NAFLD | positive regulation of establishment of protein localization | 55/1882 | 319/18723 | 4.79e-05 | 1.14e-03 | 55 |
| GO:19033647 | Liver | NAFLD | positive regulation of cellular protein catabolic process | 29/1882 | 155/18723 | 7.37e-04 | 9.36e-03 | 29 |
| GO:20000607 | Liver | NAFLD | positive regulation of ubiquitin-dependent protein catabolic process | 22/1882 | 107/18723 | 8.56e-04 | 1.05e-02 | 22 |
| GO:00903166 | Liver | NAFLD | positive regulation of intracellular protein transport | 29/1882 | 160/18723 | 1.24e-03 | 1.41e-02 | 29 |
| GO:00725947 | Liver | NAFLD | establishment of protein localization to organelle | 62/1882 | 422/18723 | 1.48e-03 | 1.64e-02 | 62 |
| GO:19030525 | Liver | NAFLD | positive regulation of proteolysis involved in cellular protein catabolic process | 25/1882 | 133/18723 | 1.54e-03 | 1.66e-02 | 25 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARIH2 | SNV | Missense_Mutation | c.782N>A | p.Arg261His | p.R261H | O95376 | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR | |
| ARIH2 | SNV | Missense_Mutation | novel | c.1295A>T | p.Tyr432Phe | p.Y432F | O95376 | protein_coding | deleterious(0.03) | possibly_damaging(0.788) | TCGA-UC-A7PD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ARIH2 | SNV | Missense_Mutation | c.980T>C | p.Leu327Pro | p.L327P | O95376 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARIH2 | SNV | Missense_Mutation | c.923G>T | p.Gly308Val | p.G308V | O95376 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-6600-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cpt-11 | PD | |
| ARIH2 | SNV | Missense_Mutation | c.760N>A | p.Glu254Lys | p.E254K | O95376 | protein_coding | deleterious(0.03) | possibly_damaging(0.585) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ARIH2 | SNV | Missense_Mutation | novel | c.828N>C | p.Trp276Cys | p.W276C | O95376 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ARIH2 | SNV | Missense_Mutation | novel | c.323N>A | p.Arg108Lys | p.R108K | O95376 | protein_coding | tolerated(0.85) | benign(0.014) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ARIH2 | SNV | Missense_Mutation | novel | c.323N>T | p.Arg108Ile | p.R108I | O95376 | protein_coding | tolerated(0.14) | possibly_damaging(0.473) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARIH2 | SNV | Missense_Mutation | novel | c.1244N>G | p.Lys415Arg | p.K415R | O95376 | protein_coding | tolerated(0.41) | benign(0.001) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ARIH2 | SNV | Missense_Mutation | novel | c.118G>A | p.Val40Met | p.V40M | O95376 | protein_coding | tolerated(0.13) | benign(0.038) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |